2 Sources
[1]
History Says These Could Be 3 of the Best Healthcare Stocks to Own in the Second Half of 2024 | The Motley Fool
These are solid stocks that have all generated 10-year returns in excess of 200%. The S&P 500 has remained red hot, achieving gains of nearly 15% through the first six months of 2024. Healthcare stocks have performed well, but not nearly to the same extent -- the Healthcare Select Sector SPDR ETF
[2]
History Says These Could Be 3 of the Best Healthcare Stocks to Own in the Second Half of 2024
The S&P 500 has remained red hot, achieving gains of nearly 15% through the first six months of 2024. Healthcare stocks have performed well, but not nearly to the same extent -- the Healthcare Select Sector SPDR ETF has risen by 7% during the first half of this year. Healthcare stocks may not
Share
Copy Link
Historical performance and market trends point to three healthcare stocks that could be promising investments for the latter half of 2024. These companies have shown resilience and growth potential in the ever-evolving healthcare sector.

As we move into the second half of 2024, investors are keenly eyeing the healthcare sector for potential opportunities. Historical data and market trends have highlighted three healthcare stocks that could be particularly promising investments. These companies have demonstrated consistent performance and adaptability in the face of changing market conditions
1
.UnitedHealth Group (NYSE: UNH) stands out as a frontrunner in the healthcare industry. As the largest health insurer in the United States, UnitedHealth has consistently delivered strong financial results. The company's diversified business model, which includes health insurance, pharmacy benefits management, and healthcare delivery, has contributed to its resilience in various market conditions
2
.Johnson & Johnson (NYSE: JNJ) continues to be a stalwart in the healthcare sector. The company's recent strategic decision to spin off its consumer health division has allowed it to focus more intently on its pharmaceutical and medical device segments. This move is expected to drive innovation and potentially lead to increased shareholder value in the coming months
1
.Eli Lilly (NYSE: LLY) has gained significant attention due to its groundbreaking developments in diabetes and obesity treatments. The company's GLP-1 receptor agonists have shown promising results in clinical trials, potentially revolutionizing the treatment landscape for these conditions. This innovation has positioned Eli Lilly as a key player in the pharmaceutical industry
2
.Related Stories
The healthcare sector is experiencing rapid technological advancements and increasing demand for innovative treatments. These factors, combined with an aging global population, are expected to drive growth in the industry. The three highlighted companies are well-positioned to capitalize on these trends, given their strong market presence and focus on research and development
1
.While historical performance and current market trends suggest potential for these stocks, investors should conduct thorough research and consider their individual financial goals before making investment decisions. Factors such as regulatory changes, competition, and global economic conditions can impact the performance of healthcare stocks
2
.As the second half of 2024 unfolds, UnitedHealth Group, Johnson & Johnson, and Eli Lilly remain stocks to watch in the healthcare sector. Their historical performance, coupled with their strategic positioning in the market, makes them potentially attractive options for investors looking to capitalize on the growing healthcare industry.
Summarized by
Navi
[1]
1
Technology

2
Technology

3
Policy and Regulation
